Plasmodium Falciparum Dihydroorotate Dehydrogenase: A Drug Target against Malaria

References

• World Health Organization . World Malaria Report (2016).
   Google Scholar
• Garcia LS Walker NF Nadjm B et al. Malaria. Clin. Lab. Med.30 (1), 93 – 129 (2010).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention . Malaria: about malaria: biology: malaria parasites (2012). http://www.cdc.gov/malaria/about/biology/parasites.html .
   Google Scholar
• Greenwood BM Bojang K Whitty CJM Targett GAT . Malaria. Lancet365 (9469), 1487 – 1498 (2014).
   Google Scholar
• Rappuoli R Aderem A . A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature473 (7348), 463 – 469 (2011).
   PubMed Web of Science ®Google Scholar
• O'Neill PM Barton VE Ward SA . The molecular mechanism of action of artemisinin – the debate continues. Molecules15 (3), 1705 – 1721 (2010).
   PubMed Web of Science ®Google Scholar
• Seder RA Chang L-J Enama ME et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science341 (6152), 1359 – 1365 (2013). http://www.sciencemag.org/cgi/doi/10.1126/science.1241800 .
   PubMed Web of Science ®Google Scholar
• Raj DK Nixon CP Nixon CE et al. Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Science344 (6186), 871 – 877 (2014). http://www.sciencemag.org/cgi/doi/10.1126/science.1254417 .
   PubMed Web of Science ®Google Scholar
• Teixeira C Vale N Pérez B Gomes A Gomes JRBB Gomes P . “Recycling” classical drugs for malaria. American Chemical Society. http://pubs.acs.org/doi/abs/10.1021/cr500123g .
   Google Scholar
• Leite FHA da Fonseca AL Nunes RR Comar Júnior M de P Varotti F Taranto AG . Malaria: from old drugs to new molecular targets. Biochem. Biotechnol. Reports2 (4), 59 – 76 (2013). http://www.uel.br/revistas/uel/index.php/bbr/article/viewFile/16983/14196 .
   Google Scholar
• Staines HM Krishna S ( Eds). Treatment and Prevention of Malaria. Springer, Basel, Switzerland (2012). https://doi.org/10.1007/978-3-0346-0480-2.
   Google Scholar
• Wells TNC van Huijsduijnen RH Van Voorhis WC . Malaria medicines: a glass half full?Nat. Rev. Drug Discov.14 (6), 424 – 442 (2015).
   PubMed Web of Science ®Google Scholar
• Kaur K Jain M Reddy RP Jain R . Quinolines and structurally related heterocycles as antimalarials. Eur. J. Med. Chem.45 (8), 3245 – 3264 (2010).
   PubMed Web of Science ®Google Scholar
• World Health Organization . World Malaria Report 2015 (2015).
   Google Scholar
• Barnett DS Guy RK . Antimalarials in development in 2014. Chem. Rev.114 (22), 11221 – 11241 (2014).
   PubMed Web of Science ®Google Scholar
• Na-Bangchang K Karbwang J . Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development. Fundam. Clin. Pharmacol.23 (4), 387 – 409 (2009).
   PubMed Web of Science ®Google Scholar
• Huang M Graves LM . De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. Cell. Mol. Life Sci.60 (2), 321 – 336 (2003).
   PubMed Web of Science ®Google Scholar
• Cassera MB Zhang Y Hazleton KZ Schramm VL . Purine and pyrimidine pathways as targets in Plasmodium falciparum. Curr. Top. Med. Chem.11 (16), 2103 – 2115 (2011).
   PubMed Web of Science ®Google Scholar
• Liechti G Goldberg JB . Helicobacter pylori relies primarily on the purine salvage pathway for purine nucleotide biosynthesis. J. Bacteriol.194 (4), 839 – 854 (2012).
   PubMed Web of Science ®Google Scholar
• Breedveld FC Dayer JM . Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis.59 (11), 841 – 849 (2000).
   PubMed Web of Science ®Google Scholar
• Gao G Nara T Nakajima-Shimada J Aoki T . Novel organization and sequences of five genes encoding all six enzymes for de novo pyrimidine biosynthesis in Trypanosoma cruzi. J. Mol. Biol.285 (1), 149 – 161 (1999).
   PubMed Web of Science ®Google Scholar
• Jones ME . Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. Annu. Rev. Biochem.49 (1), 253 – 279 (1980).
   PubMedGoogle Scholar
• Feliciano PR Cordeiro AT Costa-Filho AJ Nonato MC . Cloning, expression, purification, and characterization of Leishmania major dihydroorotate dehydrogenase. Protein Expr. Purif.48 (1), 98 – 103 (2006).
   PubMed Web of Science ®Google Scholar
• Hines V Johnston M . Analysis of the kinetic mechanism of the bovine liver mitochondrial dihydroorotate dehydrogenase. Biochemistry28, 1222 – 1226 (1989).
   PubMed Web of Science ®Google Scholar
• Reis RAG Ferreira P Medina M Nonato MC . The mechanistic study of Leishmania major dihydro-orotate dehydrogenase based on steady- and pre-steady-state kinetic analysis. Biochem. J.473 (5), 651 – 660 (2016).
   PubMedGoogle Scholar
• Lieberman I Kornberg A . Enzymic synthesis and breakdown of a pyrimidine, orotic acid. Biochim. Biophys. Acta12 (1–2), 223 – 234 (1953).
   PubMedGoogle Scholar
• Dimitrijevic M Bartlett RR . Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis. Inflamm. Res.45 (11), 550 – 556 (1996).
   PubMed Web of Science ®Google Scholar
• Smolen JS Kalden JR Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet353 (9149), 259 – 266 (1999).
   PubMed Web of Science ®Google Scholar
• Rowland P Bjornberg O Nielsen FS Jensen KF Larsen S . The crystal structure of Lactococcus lactis dihydroorotate dehydrogenase A complexed with the enzyme reaction product throws light on its enzymatic function. Protein Sci.7 (6), 1269 – 1279 (1998).
   PubMed Web of Science ®Google Scholar
• Knecht W Henseling J Löffler M . Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem. Biol. Interact.124 (1), 61 – 76 (2000).
   PubMed Web of Science ®Google Scholar
• Vyas VK Ghate M . Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Mini Rev. Med. Chem.11 (12), 1039 – 1055 (2011).
   PubMed Web of Science ®Google Scholar
• Munier-Lehmann H Vidalain PO Tangy F Janin YL . On dihydroorotate dehydrogenases and their inhibitors and uses. J. Med. Chem.56 (8), 3148 – 3167 (2013).
   PubMed Web of Science ®Google Scholar
• Pinheiro MP Emery FDS Nonato MC . Target sites for the design of anti-trypanosomatid drugs based on the structure of dihydroorotate dehydrogenase. Curr. Pharm. Des.19 (14), 2615 – 2627 (2013).
   PubMed Web of Science ®Google Scholar
• Hille R Miller S Palfey B et al. Handbook of Flavoproteins (Volume 1): Oxidases, Dehydrogenases and Related Systems . https://faculty.missouri.edu/∼tannerjj/tannergroup/pdfs/HandBookFlavoproteinstoc.pdf .
   Google Scholar
• Sulyok M Rückle T Roth A et al. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect. Dis.17 (6), 636 – 644 (2017).
   PubMed Web of Science ®Google Scholar
• Murphy SC Duke ER Shipman KJ et al. A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic Plasmodium falciparum infection during controlled human malarial infection by mosquito bites and direct venous inoculation. J. Infect. Dis.217 (5), 693 – 702 (2018). https://academic.oup.com/jid/article/217/5/693/4690588 .
   PubMed Web of Science ®Google Scholar
• McCarthy JS Lotharius J Rückle T et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human Phase 1a/1b randomised study. Lancet Infect. Dis.17 (6), 626 – 635 (2017).
   PubMed Web of Science ®Google Scholar
• Phillips MA Lotharius J Marsh K et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci. Transl. Med.7 (296), 296ra111 – 296ra111 (2015). http://stm.sciencemag.org/content/7/296/296ra111%5Cnhttp://stm.sciencemag.org/cgi/doi/10.1126/scitranslmed.aaa6645 .
   PubMed Web of Science ®Google Scholar
• Baldwin J Farajallah AM Malmquist NA Rathod PK Phillips MA . Malarial dihydroorotate dehydrogenase: substrate and inhibitor specificity. J. Biol. Chem.277 (44), 41827 – 41834 (2002).
   PubMed Web of Science ®Google Scholar
• Björnberg O Rowland P Larsen S Jensen KF . Active site of dihydroorotate dehydrogenase A from Lactococcus lactis investigated by chemical modification and mutagenesis. Biochemistry36 (51), 16197 – 16205 (1997).
   PubMed Web of Science ®Google Scholar
• Sorensen PG Dandanell G . A new type of dihydroorotate dehydrogenase, type 1S, from the thermoacidophilic archaeon Sulfolobus solfataricus. Extremophiles6 (3), 245 – 251 (2002).
   PubMed Web of Science ®Google Scholar
• Liu S Neidhardt EA Grossman TH Ocain T Clardy J . Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure8 (1), 25 – 33 (2000).
   PubMed Web of Science ®Google Scholar
• Norager S Jensen KF Björnberg O Larsen S . E. coli dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenases. Structure10 (9), 1211 – 1223 (2002).
   PubMed Web of Science ®Google Scholar
• Couto SG Cristina Nonato M Costa-Filho AJ . Site directed spin labeling studies of Escherichia coli dihydroorotate dehydrogenase N-terminal extension. Biochem. Biophys. Res. Commun.414 (3), 487 – 492 (2011).
   PubMed Web of Science ®Google Scholar
• Couto SG Nonato MC Costa-Filho AJ . Defects in vesicle core induced by Escherichia coli dihydroorotate dehydrogenase. Biophys. J.94 (5), 1746 – 1753 (2008).
   PubMed Web of Science ®Google Scholar
• Nielsen FS Andersen PS Jensen KF . The B form of dihydroorotate dehydrogenase from Lactococcus lactis consists of two different subunits, encoded by the pyrDb and pyrK genes, and contains FMN, FAD, and [FeS] redox centers. J. Biol. Chem.271 (46), 29359 – 29365 (1996).
   PubMed Web of Science ®Google Scholar
• Rowland P N⊘rager S Jensen KF Larsen S . Structure of dihydroorotate dehydrogenase B: electron transfer between two flavin groups bridged by an iron-sulphur cluster. Structure8 (12), 1227 – 1238 (2000).
   PubMed Web of Science ®Google Scholar
• Singh A Maqbool M Mobashir M Hoda N . Dihydroorotate dehydrogenase: a drug target for the development of antimalarials. Eur. J. Med. Chem.125, 640 – 651 (2017).
   PubMed Web of Science ®Google Scholar
• Robert X Gouet P . Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res.42 (W1), W320–W324 (2014).
   Web of Science ®Google Scholar
• Hurt DE Widom J Clardy J . Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. Acta Crystallogr. Sect. D Biol. Crystallogr.62 (3), 312 – 323 (2006).
   PubMedGoogle Scholar
• Ross LS Gamo FJ Lafuente-Monasterio MJ et al. In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth. J. Biol. Chem.289 (26), 17980 – 17995 (2014).
   PubMed Web of Science ®Google Scholar
• Booker ML Bastos CM Kramer ML et al. Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model. J. Biol. Chem.285 (43), 33054 – 33064 (2010).
   PubMed Web of Science ®Google Scholar
• Coteron JM Marco MM Esquivias J et al. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J. Med. Chem.54 (15), 5540 – 5561 (2011).
   PubMed Web of Science ®Google Scholar
• Deng X Gujjar R El Mazouni F et al. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds. J. Biol. Chem.284 (39), 26999 – 27009 (2009).
   PubMed Web of Science ®Google Scholar
• Deng X Kokkonda S El Mazouni F et al. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors. J. Med. Chem.57 (12), 5381 – 5394 (2014).
   PubMed Web of Science ®Google Scholar
• Deng X Matthews D Rathod PK Phillips MA . The x-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions. Acta Crystallogr. F Struct. Biol. Commun.71, 553 – 559 (2015).
   PubMed Web of Science ®Google Scholar
• Kokkonda S Deng X White KL et al. Tetrahydro-2-naphthyl and 2-indanyl triazolopyrimidines targeting Plasmodium falciparum dihydroorotate dehydrogenase display potent and selective antimalarial activity. J. Med. Chem.59 (11), 5416 – 5431 (2016).
   PubMed Web of Science ®Google Scholar
• Phillips MA White KL Kokkonda S et al. A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria. ACS Infect. Dis.2 (12), 945 – 957 (2016).
   PubMed Web of Science ®Google Scholar
• Walse B Dufe VT Svensson B et al. The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites. Biochemistry47 (34), 8929 – 8936 (2008).
   PubMed Web of Science ®Google Scholar
• Argyrou A Washabaugh MW Pickart CM . Dihydroorotate dehydrogenase from Clostridium oroticum is a class 1B enzyme and utilizes a concerted mechansim of catalysis. Biochemistry39 (34), 10373 – 10384 (2000).
   PubMed Web of Science ®Google Scholar
• Marcinkeviciene J Jiang W Locke G Kopcho LM Rogers MJ Copeland RA . A second dihydroorotate dehydrogenase (Type A) of the human pathogen Enterococcus faecalis: expression, purification, and steady-state kinetic mechanism. Arch. Biochem. Biophys.377 (1), 178 – 186 (2000).
   PubMed Web of Science ®Google Scholar
• Malmquist NA . On the oxidative half-reaction of Plasmodium falciparum dihydroorotate dehydrogenase (PhD thesis) (2007). https://repositories.tdl.org/utswmed-ir/bitstream/handle/2152.5/417/malmquistnicholas.pdf .
   Google Scholar
• Malmquist NA Gujjar R Rathod PK Phillips MA . Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase. Biochemistry47 (8), 2466 – 2475 (2008).
   PubMed Web of Science ®Google Scholar
• Zameitat E Freymark G Dietz CD Löffler M Bölker M . Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of Ustilago maydis allows target validation of DHODH inhibitors in vivo. Appl. Environ. Microbiol.73 (10), 3371 – 3379 (2007).
   PubMed Web of Science ®Google Scholar
• Caballero I Lafuente MJ Gamo FJ Cid C . A high-throughput fluorescence-based assay for Plasmodium dihydroorotate dehydrogenase inhibitor screening. Anal. Biochem.506, 13 – 21 (2016).
   PubMed Web of Science ®Google Scholar
• Hines V Keys LD Johnston M . Purification and properties of the bovine liver mitochondrial dihydroorotate dehydrogenase. J. Biol. Chem.261 (24), 11386 – 11392 (1986).
   PubMed Web of Science ®Google Scholar
• McLean JE Neidhardt EA Grossman TH Hedstrom L . Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase. Biochemistry40 (7), 2194 – 2200 (2001).
   PubMed Web of Science ®Google Scholar
• Szymański P Markowicz M Mikiciuk-Olasik E . Adaptation of high-throughput screening in drug discovery-toxicological screening tests. Int. J. Mol. Sci.13 (1), 427 – 452 (2012).
   PubMed Web of Science ®Google Scholar
• Baldwin J Michnoff CH Malmquist NA et al. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem.280 (23), 21847 – 21853 (2005).
   PubMed Web of Science ®Google Scholar
• Phillips MA Gujjar R Malmquist NA et al. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. J. Med. Chem.51 (12), 3649 – 3653 (2008).
   PubMed Web of Science ®Google Scholar
• Gujjar R Marwaha A Mazouni F El et al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J. Med. Chem.52 (7), 1864 – 1872 (2009).
   PubMed Web of Science ®Google Scholar
• Patel V Booker M Kramer M et al. Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem.283 (50), 35078 – 35085 (2008).
   PubMed Web of Science ®Google Scholar
• Ross LS Lafuente-Monasterio MJ Sakata-Kato T et al. Identification of collateral sensitivity to dihydroorotate dehydrogenase inhibitors in Plasmodium falciparum. ACS Infect. Dis.4 (4), 508 – 515 (2018).
   PubMed Web of Science ®Google Scholar
• Hoelz LVBLV Zorzanelli BCBC Azevedo PHR de APH et al. Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5. Eur. J. Med. Chem.112, 39 – 47 (2016).
   PubMed Web of Science ®Google Scholar
• Araújo JQJQ De Brito MAAMA Hoelz LVBLVBB et al. Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE). Eur. J. Med. Chem.46 (1), 39 – 51 (2011).
   PubMed Web of Science ®Google Scholar
• Hoelz LVB Ribeiro AAST Bernardi RC et al. The role of helices 5 and 6 on the human β 1-adrenoceptor activation mechanism. Mol. Simul.38 (3), 236 – 240 (2012).
   Web of Science ®Google Scholar
• Hoelz LVB Horta BAC Araújo JQ Albuquerque MG de Alencastro RB da Silva JFM . Quantitative structure–activity relationships of antioxidant phenolic compounds. J. Chem. Pharm. Res.2 (5), 291 – 306 (2010).
   Google Scholar
• Hoelz LVB Bernardi RC Horta BAC et al. Dynamical behaviour of the human β1-adrenoceptor under agonist binding. Mol. Simul.37 (11), 907 – 913 (2011).
   Web of Science ®Google Scholar
• Hoelz LVB Leal VF Rodrigues CR et al. Molecular dynamics simulations of the free and inhibitor-bound cruzain systems in aqueous solvent: insights on the inhibition mechanism in acidic pH. J. Biomol. Struct. Dyn.34 (9), 1969 – 1978 (2016).
   PubMed Web of Science ®Google Scholar
• Heikkilä T Thirumalairajan S Davies M et al. The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorganic Med. Chem. Lett.16 (1), 88 – 92 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenfeld RJ Goodsell DS Musah RA Morris GM Goodin DB Olson AJ . Automated docking of ligands to an artificial active site: augmenting crystallographic analysis with computer modeling. J. Comput. Aided. Mol. Des.17 (8), 525 – 536 (2003).
   PubMed Web of Science ®Google Scholar
• Zsoldos Z Reid D Simon A Sadjad BS Johnson a P . eHiTS: an innovative approach to the docking and scoring function problems. Curr. Protein Pept. Sci.7 (5), 421 – 435 (2006).
   PubMed Web of Science ®Google Scholar
• Zsoldos Z Reid D Simon A Sadjad SB Johnson AP . eHiTS: a new fast, exhaustive flexible ligand docking system. J. Mol. Graph. Model.26 (1), 198 – 212 (2007).
   PubMed Web of Science ®Google Scholar
• Heikkilä T Ramsey C Davies M Galtier C . Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J. Med. Chem.50 (2), 186 – 191 (2007).
   PubMed Web of Science ®Google Scholar
• Davies M Heikkila T McConkey GA Fishwick CW Parsons MR Johnson AP . Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J. Med. Chem.52 (9), 2683 – 2693 (2009).
   PubMed Web of Science ®Google Scholar
• Cowen D Bedingfield P McConkey GA Fishwick CWG Johnson AP . A study of the effects of substituents on the selectivity of the binding of N-arylaminomethylene malonate inhibitors to DHODH. Bioorganic Med. Chem. Lett.20 (3), 1284 – 1287 (2010).
   PubMed Web of Science ®Google Scholar
• Morris GM Goodsell DS Halliday RS et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem.19 (14), 1639 – 1662 (1998).
   Web of Science ®Google Scholar
• Ojha PK Roy K . Chemometric modeling, docking and in silico design of triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors as antimalarials. Eur. J. Med. Chem.45 (10), 4645 – 4656 (2010).
   PubMed Web of Science ®Google Scholar
• DeLano W . Pymol: an open-source molecular graphics tool. CCP4 Newsl. Protein Crystallogr. (2002).
   Google Scholar
• Delano WL Bromberg S . PyMOL user's guide. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.120.7267&rep=rep1&type=pdf .
   Google Scholar
• Shah P Kumar S Tiwari S Siddiqi MI . 3D-QSAR studies of triazolopyrimidine derivatives of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors using a combination of molecular dynamics, docking, and genetic algorithm-based methods. J. Chem. Biol.5 (3), 91 – 103 (2012).
   PubMedGoogle Scholar
• Kim KH Greco G Novellino E Federico N . A critical review of recent CoMFA applications. Perspect. Drug Discov. Des.12–14, 257 – 315 (1998).
   Google Scholar
• Santos-Filho OAOA Forge D Hoelz LVBLVB et al. CoMFA/CoMSIA 3D-QSAR of pyrimidine inhibitors of pneumocystis carinii dihydrofolate reductase. J. Mol. Model.18 (9), 4061 – 4072 (2012).
   PubMed Web of Science ®Google Scholar
• Wadood A Ulhaq Z . In silico identification of novel inhibitors against Plasmodium falciparum dihydroorate dehydrogenase. J. Mol. Graph. Model.40, 40 – 47 (2013).
   PubMed Web of Science ®Google Scholar
• Jones G Willett P Glen RC Leach AR Taylor R . Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol.267 (3), 727 – 748 (1997). www.sciencedirect.com/science/article/pii/S0022283696908979 .
   PubMed Web of Science ®Google Scholar
• Tseng TS Lee YC Hsiao NW Liu YR Tsai KC . Comparative study between 3D-QSAR and docking-based pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors. Bioorganic Med. Chem. Lett.26 (2), 265 – 271 (2016).
   PubMed Web of Science ®Google Scholar
• Pavadai E El Mazouni F Wittlin S de Kock C Phillips MA Chibale K . Identification of new human malaria parasite Plasmodium falciparum dihydroorotate dehydrogenase inhibitors by pharmacophore and structure-based virtual screening. J. Chem. Inf. Model.56 (3), 548 – 562 (2016).
   PubMed Web of Science ®Google Scholar
• Hou X Chen X Zhang M Yan A . QSAR study on the antimalarial activity of Plasmodium falciparum dihydroorotate dehydrogenase (Pf DHODH) inhibitors. SAR QSAR Environ. Res.27 (2), 101 – 124 (2016).
   PubMed Web of Science ®Google Scholar
• Azeredo LFSP Coutinho JP Jabor VAP et al. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors. Eur. J. Med. Chem.126, 72–83 (2017).
   PubMed Web of Science ®Google Scholar
• Morris GM Huey R Lindstrom W et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem.30 (16), 2785 – 2791 (2009).
   PubMed Web of Science ®Google Scholar
• McConkey GA Bedingfield PTP Burrell DR et al. Interconvertible geometric isomers of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors exhibit multiple binding modes. Bioorg. Med. Chem. Lett.27 (16), 3878 – 3882 (2017).
   PubMed Web of Science ®Google Scholar
• Gujjar R El Mazouni F White KL et al. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J. Med. Chem.54 (11), 3935 – 3949 (2011).
   PubMed Web of Science ®Google Scholar
• Marwaha A White J El-mazouni F et al. Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenase. J. Med. Chem.55 (17), 7425 – 7436 (2012).
   PubMed Web of Science ®Google Scholar
• Xu M Zhu J Diao Y et al. Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives. J. Med. Chem.56 (20), 7911 – 7924 (2013).
   PubMed Web of Science ®Google Scholar
• Skerlj RT Bastos CM Booker ML et al. Optimization of potent inhibitors of P. falciparum dihydroorotate dehydrogenase for the treatment of malaria. ACS Med. Chem. Lett.2 (9), 708 – 713 (2011).
   PubMed Web of Science ®Google Scholar
• Schrader FC Barho M Steiner I Ortmann R Schlitzer M . The antimalarial pipeline–an update. Int. J. Med. Microbiol.302 (4–5), 165 – 171 (2012). http://www.sciencedirect.com/science/article/pii/S1438422112000379 .
   PubMed Web of Science ®Google Scholar
• Anthony MP Burrows JN Duparc S Jmoehrle J Wells TNC . The global pipeline of new medicines for the control and elimination of malaria. Malar. J.11, 316 (2012).
   PubMed Web of Science ®Google Scholar
• MMV-supported projects: Medicines for Malaria Venture. https://www.mmv.org/research-development/mmv-supported-projects .
   Google Scholar
• Medicines for Malaria Venture . Malaria treatment. https://www.mmv.org/malaria-medicines/malaria-treatment .
   Google Scholar